Revolution Medicines

RVMD

Market cap $23.8B

Revolution Medicines, Inc. (RVMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

It's apparently in talks to be sold to a pharmaceutical industry titan. The price being discussed reaches into the tens of billions of dollars.

Revolution is developing drugs that target a molecular driver of cancers.

Revolution Medicines (RVMD) remains a "Strong Buy", driven by advanced RAS [ON] inhibitor programs and robust clinical progress, notably with Daraxonrasib. Company's phase 3 RASolute-302 trial in metastatic PDAC RAS-mutant patients is a major catalyst, with data expected in 2026 and significant expansion potential. Buyout interest from major pharma, including rumored $28–32B bids, underscores RVMD's strategic value and enhances upside optionality.

Merck is in talks to acquire RVMD, which could bolster its oncology pipeline, according to a Financial Times report.

Revolution Medicines stock was soaring again early Friday after a report that Merck is in talks to buy the cancer-drug biotech for up to $32 billion.

Merck is in talks to buy cancer drug developer Revolution Medicines , the Financial Times reported on Thursday, citing people familiar with the matter.

Revolution Medicines shares jump nearly 29% to a record high after a WSJ report said AbbVie showed takeover interest, a claim the pharma giant later denied.

Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapy First Breakthrough Therapy Designation for an investigational drug specifically targeting KRAS G12D mutation in NSCLC Revolution Medicines' third RAS(ON) inhibitor to receive this designation REDWOOD CITY, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to zoldonrasib, a RAS(ON) G12D-selective inhibitor, for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic NSCLC who have been previously treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapy.

Shareholders in both drugmakers appear disappointed that a deal may not happen.